OBJECTIVES The purpose of this study was to investigate changes in the use of transcatheter aortic valve replacement (TAVR) relative to surgical aortic valve replacement (SAVR) and to examine relative 1-year TAVR and SAVR outcomes in 2011 to 2012 in a population-based setting.
U
ntil recently, many patients with severe symptomatic aortic stenosis were not candidates for surgical intervention via surgical aortic valve replacement (SAVR) because their perioperative risk was thought to be too high. However, with the introduction of transcatheter aortic valve replacement (TAVR), many of these patients have been faring better than they would have with medical treatment alone. Also, TAVR has become an option for patients who are operable but have very high short-term risks with SAVR, and numerous randomized controlled trials and observational studies have shown that TAVR outcomes are frequently as good or better than SAVR outcomes . However, for the most part, these studies were limited to very high-risk patients or examined short-term outcomes (29, 30) .
TAVR is now used in some settings for moderaterisk as well as high-risk patients, and information about the use of TAVR in standard practice for lowerrisk patients is limited and based on small samples.
The purposes of this study were to compare 1-year mortality rates for TAVR and SAVR after having OUTCOMES. The outcomes of interest are all-cause in-hospital/30-day mortality and 1-year mortality.
Only patients who could be followed for an entire year were included in the 1-year mortality part of Propensity score matching was used to identify a set of TAVR/SAVR pairs matched on all available characteristics so that the selection bias associated with our observational study could be minimized.
The propensity score was derived by developing a logistic regression model that predicted the probability that a given patient would receive TAVR on the basis of all of the risk factors available in the registry. The mortality rates were also compared for patients in 2 ranges (<3% and $3%) of pre-procedural short-term risk, and for subsets of patients (age <80 and $80 years, nonfrail patients). The analyses were repeated with propensity matching that required each matched pair of patients to be from the same hospital to ensure that variable hospital quality did not affect the results. The findings were essentially unchanged and are not reported here. All tests were 2-sided and conducted at the p ¼ 0.05 level, and all analyses were conducted in SAS version 9.2 (SAS Institute, Cary, North Carolina). Table 1 After exclusions, 1,545 SAVR patients and 747 TAVR patients were candidates for propensity matching. As demonstrated, the standardized differences for most risk factors exceeded the recommended maximum value of 10%, with TAVR patients generally having higher prevalences ( Table 2) . Before propensity matching, the median NYS score for TAVR patients was 4.91% and the median score for SAVR patients was 2.13% (p < 0.001).
RESULTS
A total of 405 pairs resulted from the propensity match. The propensity model has a very good discrimination, with C statistic of 0.881 and acceptable calibration (p ¼ 0.08). Also, standardized differences for all variables were lower than the typical cutoff of 10% for this measure ( Table 3 ). The median NYS score for propensity-matched TAVR patients was 3.74, and the median score for SAVR patients was 3.93
The respective in-hospital/30-day mortality results for TAVR and SAVR patients were 5.49% and 2.52% (p < 0.001) prior to propensity matching, and 4.69% Table 4 ). There were no significant differences between the procedures for the 2 ranges of NYS scores: 12.5% vs. 10.3%; HR: 1.42 (95% CI: 0.68 to 2.97) for NYS score <3% and 17.10% vs. 14.5%; HR:
1.27 (95% CI: 0.81 to 1.98) for patients with NYS score $3%. There were also no differences between the mortality rates for the 2 procedures for patients age <80 and $80 years or for patients without frailty. Values are n (%).
DISCUSSION
Abbreviations as in Tables 1 and 2 .
Hannan et al.
procedures (from 297 to 764, an increase of 157%).
Also, there was a decrease in the proportion of higher- The findings of our study are in accord with the findings of the observational study by Piazza et al.
(31), which found no differences at 1 year either for patients with 3% to 8% STS scores or for patients with <3% scores (note that the cutoff point of 3%
NYS score is essentially the same as an 8% STS score). However, it is important to note that although the HRs in our study were not significant, WHAT IS NEXT? With the increasing use of TAVR among lower-risk patients, it will be important to determine which types of patients experience superior outcomes for each type of aortic valve replacement as utilization patterns and procedural improvements occur.
